Compare Aecom (ACM) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aecom vs Charles River Laboratories Intl. Inc — how do they compare? Aecom trades at $62.29 (market cap $8.62B), while Charles River Laboratories Intl. Inc trades at $286.59 (market cap $13.46B). The key difference: Charles River Laboratories Intl. Inc is the larger of the two by market cap, and Aecom pays a 1.77% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| ACM | CRL | |
|---|---|---|
Market Cap | $8.62B | $13.46B |
Sector | Industrials | Health |
52-Week High | $134.35 | $282.00 |
52-Week Low | $66.86 | $145.57 |
Enterprise Value | $10.81B | $16.30B |
Dividend Yield | 1.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACM's stock is trading at $73.30, down 3.35% in the last session, reflecting negative momentum after a Q2 2026 earnings miss. The technical outlook is bearish, with support at $72 and resistance at $76. Fundamentally, revenue reached $16.14 billion in 2025, but net income margin is thin at 1.87%, and ROE is negative. Recent news includes a securities investigation announcement and a large project charge impacting earnings.
The investment outlook is mixed: analyst consensus is bullish with a $88.25 price target, but risks include earnings volatility, a fraud probe, and rising debt-to-asset ratio. Opportunities lie in record backlog growth and new project wins like the Lisbon airport design. Investors should weigh strong institutional support against operational and legal headwinds.
Charles River Laboratories (CRL) trades at $277.00, up 3.56% on the day and near its 52-week high of $277.07, reflecting strong bullish momentum. The stock exhibits positive technical signals with moving averages indicating an uptrend, though oscillators suggest overbought conditions. Fundamentally, the company reported Q2 2026 EPS of $3.02, beating estimates, and raised full-year guidance, yet faces profitability challenges with a negative net income margin of -5.96% and elevated valuation ratios like a P/E of 684.85. Recent news highlights improved biotech demand and institutional buying interest.
The outlook for CRL is cautiously optimistic, driven by earnings beats and raised guidance, but high valuation and weak profitability pose risks. Investment opportunity lies in sustained demand for drug development services, while risks include margin pressure, debt levels, and sensitivity to biotech funding cycles. The stock's proximity to all-time highs warrants monitoring for pullbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aecom
Aecom is one of the largest global providers of design, engineering, construction, and management services. The firm serves a broad spectrum of end markets including infrastructure, water, transportation, and energy. Based in Los Angeles, Aecom has a presence in over 150 countries and employs 51,000. The company generated $13.3 billion in sales and $701 million in adjusted operating income in fiscal 2021.
Read more on ACM →About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →
